Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar

Journal of Nuclear Medicine

Volumn 56, Issue 1, 2015, Pages 82-87

  Kreisl, William C ^a,b   Bhatia, Ritwik ^a   Morse, Cheryl L ^a   Woock, Alicia E ^a   Zoghbi, Sami S ^a   Shetty, H Umesha ^a   Pike, Victor W ^a   Innis, Robert B ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

N desmethyl loperamide; P glycoprotein (P gp); Positron emission tomography (PET); Tariquidar

Indexed keywords

CARBON 11; DISULFIRAM; GLYCOPROTEIN; N DESMETHYL LOPERAMIDE C 11; TARIQUIDAR; UNCLASSIFIED DRUG; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN; N-DEMETHYLLOPERAMIDE; QUINOLINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN REGION; DRUG BRAIN LEVEL; DRUG MEGADOSE; DRUG PENETRATION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; IMAGE QUALITY; LOW DRUG DOSE; MALE; METALLIC TASTE; NAUSEA; NEOCORTEX; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DIAGNOSTIC USE; DOSE RESPONSE; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; PERMEABILITY; SAFETY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LOPERAMIDE; MALE; P-GLYCOPROTEIN; PERMEABILITY; POSITRON-EMISSION TOMOGRAPHY; QUINOLINES; SAFETY;

EID: 84920428844     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.114.146894     Document Type: Article

References (21)

1. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002; 53: 615-627.
2. Kalvass JC, Pollack GM. Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharm Res. 2007; 24: 265-276.
3. Kannan P, John C, Zoghbi SS, et al. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther. 2009; 86: 368-377.
4. 11C-N-desmethylloperamide. J Nucl Med. 2010; 51: 559-566.
5. 11C-N-desmethyl-loperamide in monkeys. J Nucl Med. 2009; 50: 108-115.
6. 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein. J Nucl Med. 2009; 50: 807-813.
7. 11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. Clin Pharmacol Ther. 2012; 91: 227-233.
8. 11C-verapamil and PET. J Nucl Med. 2009; 50: 1954-1961.
9. Stewart A, Steiner J, Mellows G, Laguda B, Norris D, Bevan P. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD561 lymphocytes after oral and intravenous administration. Clin Cancer Res. 2000; 6: 4186-4191.
10. Loo TW, Bartlett MC, Clarke DM. Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein. Mol Pharm. 2004; 1: 426-433.
11. Loo TW, Clarke DM. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J Natl Cancer Inst. 2000; 92: 898-902.
12. Sauna ZE, Peng XH, Nandigama K, Tekle S, Ambudkar SV. The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1). Mol Pharmacol. 2004; 65: 675-684.
13. 11C] N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. J Med Chem. 2008; 51: 6034-6043.
14. Choo EF, Kurnik D, Muszkat M, et al. Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier. J Pharmacol Exp Ther. 2006; 317: 1012-1018.
15. Kurnik D, Sofowora GG, Donahue JP, et al. Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein. Anesthesiology. 2008; 109: 1092-1099.
16. Pusztai L, Wagner P, Ibrahim N, et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer. 2005; 104: 682-691.
17. Abraham J, Edgerly M, Wilson R, et al. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res. 2009; 15: 3574-3582.
18. Enghusen Poulsen H, Loft S, Andersen JR, Andersen M. Disulfiram therapy: adverse drug reactions and interactions. Acta Psychiatr Scand Suppl. 1992; 369: 59-65.
19. Kannan P, Brimacombe KR, Kreisl WC, et al. Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET. Proc Natl Acad Sci USA. 2011; 108: 2593-2598.
20. Kannan P, Telu S, Shukla S, et al. The "specific" P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci. 2011; 2: 82-89.
21. Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev. 2002; 54: 1295-1310.